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Abstract
Background: Celiac disease is a T-cell mediated chronic inflammatory disorder of the gut that is induced by dietary
exposure to gluten proteins. CD4+ T cells of the intestinal lesion recognize gluten peptides in the context of HLA-DQ2.5 or
HLA-DQ8 and the gluten derived peptides become better T-cell antigens after deamidation catalyzed by the enzyme
transglutaminase 2 (TG2). In this study we aimed to identify the preferred peptide substrates of TG2 in a heterogeneous
proteolytic digest of whole wheat gluten.
Methods: A method was established to enrich for preferred TG2 substrates in a complex gluten peptide mixture by tagging
with 5-biotinamido-pentylamine. Tagged peptides were isolated and then identified by nano-liquid chromatography
online-coupled to tandem mass spectrometry, database searching and final manual data validation.
Results: We identified 31 different peptides as preferred substrates of TG2. Strikingly, the majority of these peptides were
harboring known gluten T-cell epitopes. Five TG2 peptide substrates that were predicted to bind to HLA-DQ2.5 did not
contain previously characterized sequences of T-cell epitopes. Two of these peptides elicited T-cell responses when tested
for recognition by intestinal T-cell lines of celiac disease patients, and thus they contain novel candidate T-cell epitopes. We
also found that the intact 9mer core sequences of the respective epitopes were not present in all peptide substrates.
Interestingly, those epitopes that were represented by intact forms were frequently recognized by T cells in celiac disease
patients, whereas those that were present in truncated versions were infrequently recognized.
Conclusion: TG2 as well as gastrointestinal proteolysis play important roles in the selection of gluten T-cell epitopes in celiac
disease.
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Introduction
Celiac disease is an intestinal chronic inflammatory disorder
elicited by dietary wheat gluten and related proteins from barley and
rye. The disease is characterized by malabsorption, flattening of
mucosa and the presence of autoantibodies. The large majority of
the celiac disease patients express the HLA-DQ2.5 and/or HLA-
DQ8 molecules [1], and gluten specific T-cells restricted to these
HLA-molecules can be isolated from intestinal biopsies of the
patients[2,3].ThepeptidebindingmotifsofHLA-DQ2.5andHLA-
DQ8 have been thoroughly investigated and both molecules show a
preference for negative charges at certain anchor positions; DQ2.5
in positions P4, P6 and P7 [4–6] and DQ8 in positions P1 and P9
[7,8]. Interestingly, these restricted T cells recognize gluten peptides
onlyorpreferentiallyaftertheyundergodeamidation,amodification
which is catalyzed by the enzyme transglutaminase 2 (TG2).
TG2 is a calcium-dependent enzyme which targets specific
glutamine residues in peptides and proteins for either transamida-
tion (crosslinking) or deamidation [9]. In the transamidation
reaction, a stable isopeptide bond is formed between a peptidy-
lglutamine residue (acyl-donor) and the amino group of an acyl-
acceptor, e.g. peptidyllysine or a primary amine molecule.
Deamidation of the targeted glutamine residue results in
conversion to a glutamic acid and introduces a negative charge.
It has been demonstrated that both for the deamidation [10] and
transamidation reactions [11] the targeting of glutamine (Q)
residues in peptides is strongly influenced by the positioning of C-
terminally located proline (P) residues. Whereas a Q residue in the
QXP consensus sequence is targeted by TG2, Q residues in a QP
or QXXP sequence motif are not.
During the recent years several T-cell epitopes of wheat gluten
have been identified [12–19]. The majority of these epitopes
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to T cells in the context of HLA-DQ2.5. Notably, the gliadin
epitopes often cluster in regions rich in proline residues.
Conceivably, the selection of the T-cell epitopes is governed by
several factors: (i) T-cell epitopes are usually spanning 9–12
residues and thus protection against complete digestion in the
gastrointestinal tract imposed by proline residues is important
[20]; (ii) another selective force is exerted by TG2 as these epitopes
are dependent on deamidation by this enzyme; (iii) finally, epitope
selection by HLA seems of importance as both HLA-DQ2.5 and
HLA-DQ8 prefer binding of peptides with negatively charged
anchor residues. Importantly, all these selective forces will act in
concert.
Several recent studies have pointed towards a role of TG2 in the
selection of T-cell epitopes in celiac disease. Using a set of
synthetic overlapping peptides covering the whole sequence of a c-
gliadin protein, those peptides that were quickly deamidated by
TG2 were also recognized by T-cell lines of celiac disease patients
[11]. We have also demonstrated that the known HLA-DQ2.5-
restricted gliadin epitopes are substrates for TG2, but the rate by
which this modification occurs differs considerably between the
peptides [21]. We found a correlation between the rate of
deamidation of the different epitopes and their T cell immunos-
timulatory capacity. Finally, the finding that proline governs the
specificity of the enzyme and that gluten T-cell epitopes are rich in
proline residues further supports the notion of a selective force
exerted by TG2.
In this study we aimed to shed further light on the role of TG2
in the selection of gluten T-cell epitopes. Gluten is an extreme
complex mixture of diverse proteins. Several hundred distinct
gluten proteins are belonging to the gliadin and glutenin fractions
of a single wheat variety, and therefore tens of thousands different
peptides will be present in a digest of wheat flour. To mimic the
selection of T-cell epitopes from this vast sea of peptides that is
present in the gut after gluten ingestion, we have developed a
method to identify the preferred peptide substrates for TG2 in a
proteolytic digest of whole gluten. Interestingly, we found that the
great majority of preferred substrates for TG2 from this
heterogeneous mixture are indeed peptides that harbor known
gluten T-cell epitopes. We also discovered two peptides that
harbor novel candidate T-cell epitopes.
Materials and Methods
Synthesis of peptides and purification of recombinant
human TG2
Synthetic peptides were purchased from GL Biochem Ltd
(Shanghai, China). Recombinant human TG2 was expressed in
Escherichia coli with an N-terminal hexa-histidine tag and purified
as described previously [22] with some minor modifications [23].
Proteolysis of gluten
Whole gluten (Bob’s Red Mill, Milwaukie, Oregon) digested
with pepsin, trypsin, chymotrypsin, elastase and carboxypeptidase
(PTCEC gluten) was a gift from M. Bethune (Stanford University)
and was prepared as follows: A solution of 15 mg/ml gluten was
dissolved in 0.01 N HCL (pH,2.1) and was incubated with
0.6 mg/ml pepsin (American Laboratories) for 60 min at 37uC.
The digest was adjusted to pH 6.5 with 50 mM sodium phos-
phate buffer and incubated with 0.375 mg/ml trypsin (Sigma),
0.375 mg/ml chymotrypsin (Sigma), 0.075 mg/ml elastase (Sig-
ma) and 0.075 mg/ml carboxypeptidase A (Sigma) for 120 min at
37uC. The sample was heated to 95uC for 5 min to stop proteolysis
followed by centrifugation and filtration of the supernatants.
Validation of the enrichment procedure using synthetic
peptides
To test the specificity of the enrichment procedure, 20 mMo f
the synthetic peptides DQ2-a-I (QLQPFPQPQLPY) and DQ2-c-
II (GIIQPQQPAQL) was separately mixed with 20 mM5 -
biotinamido-pentylamine (5-BP) in 10 ml of 100 mM Tris/HCl
pH 7.4 supplemented with 2 mM CaCl2. Both samples were
incubated with 0.1 mg/ml TG2 at 37uC for 60 min before TG2
was inactivated by adding 1 ml iodoacetamide to a final
concentration of 25 mM. A volume of 1 ml of each of the samples
was added to 20 ml of 1 mg/ml PTCEC gluten digest. The sample
was incubated with 200 mg Dynabeads M270 streptavidin
(capacity: 200 pmol biotinylated peptides/1 mg beads) (Invitrogen
Dynal AS, Norway) for 30 min in PBS/0.1% SDS followed by
three washing steps each with 100 ml PBS/0.1% SDS and 100 ml
20% acetonitrile/water. For elution, beads were incubated with
15 ml 70% acetonitrile/2% formic acid/0.2 mM biotin for 30 min
at 37uC and the eluate was analyzed by MALDI-TOF mass
spectrometry (Ultraflex II, Bruker Daltonics, Bremen, Germany).
In order to rank the peptides according to their level of
transamidation, a sample containing 20 mM of each of the peptide
epitopes DQ2-a-II (PQPQLPYPQPQLPY), DQ2-c-II (GIIQPQQ-
PAQL), DQ2-c-III (FPQQPQQPYPQQP) and DQ2-c-IV (FSQP-
QQQFPQPQ) was incubated with 0.1 mg/ml TG2 and 20 mM 5-BP
in 20 ml 100 mM Tris/HCl pH 7.4 with 2 mM CaCl2 at 37uC.
Aliquots of 5 ml were removed after 1, 5 and 15 min incubation time
and 1 ml iodoacetamide (final concentration 25 mM) was added to
inactivate TG2. For enrichment, 1 ml of each of the samples was
incubated with 150 mg Dynabeads M270 streptavidin for 30 min in
PBS/0.1% SDS. Washing of the beads and elution of the enriched
biotinylated peptides was performed as described above. MALDI-
TOF spectra were acquired for the eluates of enriched transami-
dated peptides.
Further, 30 mM of a chymotryptic digest of a2-gliadin was
incubated with 0.1 mg/ml TG2 in 25 ml 100 mM Tris/HCl
pH 7.4 supplemented with 2 mM CaCl2 at 37uC for 60 min
and the reaction was terminated by adding 1 ml iodoacetamide to
a final concentration of 25 mM. The sample was purified by C18
ZipTips (Millipore, Billerica, MA, USA), the eluate was vacuum-
dried, and the peptides were redissolved in 0.1% formic acid.
Next, 300 fmol of the sample was analyzed by nano-LC coupled to
a quadrupole-time-of-flight (Q-TOF) mass spectrometer (settings
as described below). Similarly, 42 mM of a chymotryptic digest of
a2-gliadin was incubated under identical conditions in the
presence of 2 mM 5-BP. Transamidated peptides were enriched
by incubating with 150 mg Dynabeads M270 streptavidin for
30 min in PBS/0.1% SDS followed by washing of the beads as
described above. Enriched peptides were eluted by adding 10 mlo f
70% acetonitrile/2% formic acid/0.2 mM biotin and incubating
for 30 min at 37uC. Finally, MALDI-TOF spectra were acquired.
Treatment of a PTCEC gluten digest with TG2 and
enrichment of transamidated gluten peptides
A sample containing 1 mg/ml PTCEC gluten digest, 0.1 mg/ml
TG2 and 200 pmol 5-BP in 100 mM Tris/HCl pH 7.4 supple-
mented with 2 mM CaCl2 (total volume of 20 ml) was incubated at
37uCfor30 min.AfterinactivationofTG2byaddingiodoacetamide
(final concentration of 25 mM), the sample was incubated with 1 mg
DynabeadsM270streptavidinfor30 mininPBS/0.1%SDSandthe
beads were washed as described above. Enriched transamidated and
biotinylated peptides were eluted from the beads by adding 25 mlo f
70% acetonitrile/2% formic acid/0.2 mM biotin and incubating for
30 min at 37uC. Finally, the eluate was vacuum-dried.
TG2 Selects Gluten Epitopes
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The transamidated peptides enriched from PTCEC gluten were
analyzed either by a Q-TOF hybrid mass spectrometer (MicroTof-
q, Bruker Daltonics, Bremen, Germany) or an Orbitrap mass
spectrometer (LTQ Orbitrap XL, Thermo Scientific, Bremen,
Germany), both coupled to a nano-LC system. For nano-LC-Q-
TOF analysis, dried samples were dissolved in 8 ml 0.1%
trifluoroacetic acid and a volume of 6 ml was injected into an
Agilent 1100 series nano-LC system (Agilent Technologies, Palo
Alto, CA). Peptides were separated on an analytical column
(150 mm60.075 mm) packed with 100 A ˚ C18 3.5 mm particles
(G&T Septech AS, Norway). A linear gradient of 2–60% solvent B
in 60 min was applied with a flow rate of 300 nL/min (solvent A:
0.1% acetic acid/water, solvent B: 0.1% acetic acid/acetonitrile).
The Q-TOF was operated in the data-dependent mode to
automatically switch between MS and MS/MS acquisition.
Collision energies were set between 30–50 eV depending on the
charge state of the precursor ions. Data were acquired using
microTOFControl v2.0 and processed using DataAnalysis v3.4.
For nano-LC-Orbitrap analysis, the peptides were purified by C18
ZipTips (Millipore, Billerica, MA, USA), vacuum-dried and
redissolved in 10 ml of 1% formic acid, and then 3 ml were
injected into an Ultimate 3000 nanoLC system (Dionex,
Sunnyvale, CA, USA). For separation of peptides, an Acclaim
PepMap 100 column (120 mm60.075 mm) packed with 100 A ˚
C18 3 mm particles (Dionex) was used. A flow rate of 300 nL/min
was employed with a solvent gradient of 7–35% B in 77 min and
then from 35% to 50% B in 10 min (solvent A: 0.1% formic acid/
water; solvent B: 0.1% formic acid/90% acetonitrile). The mass
spectrometer was operated in the data-dependent mode to
automatically switch between Orbitrap-MS and LTQ-MS/MS
acquisition. Data were acquired using Xcalibur v2.5.
Identification of enriched transamidated gluten peptides
First, a database consisting of all known protein sequences
derived from Triticum aestivum was built by extracting entries
(n=4654) from the UniprotKB database (release 15.0) at the
European Bioinformatics Institute (EBI) using the SRS server. The
LC-MS/MS data were searched against this database using the
Mascot search engine and Proteome Discoverer software version
1.0 (Thermo Fisher Scientific Inc., Waltham, MA). In Mascot the
glutamine modification by 5-BP linkage (mass increase of
311.17 Da) was implemented and selected as variable modification
together with deamidation of glutamine and aspargine and pyro-
glutamate formation. For analysis of LTQ-Orbitrap data, the mass
tolerance was set as 10 ppm for the precursor ion and 0.6 Da for
the fragment ions, whereas for analysis of Q-TOF data the mass
tolerance was set as 0.5 Da for the precursor ion and 0.2 Da for
the fragments ions. All reported hits were in addition manually
interpreted. If the glutamine residues targeted by TG2 could not
be unambiguously assigned based on the MS/MS spectrum, also
the established rules governing the targeting of glutamine residues
by TG2 were considered [10,11]. In a few cases, extracted ion
chromatograms were generated to distinguish peptides that carry
both transamidated and deamidated glutamine residues from
peptides harboring only a transamidated glutamine residue.
T-cell assay
Twenty polyclonal T-cell lines derived from intestinal biopsies
of celiac disease patients as previously described [16] were tested
for recognition of the gluten peptides. Synthetic peptides
representing peptides #9 (VPVPQLQPQNPSQQQPQEQVPL),
#19 (PHQPQQQVPQPQQPQQPF), #25 (SHQQQPFPQQP-
YPQQPYPS), and #30 (SFPQPQPQQPQQPS) were tested in
T-cell proliferation assays after TG2 treatment done by
incubating 100 mM peptide with 0.1 mg/ml TG2 in 100 mM
Tris/HCl pH 7.4 buffer supplemented with 2 mM CaCl2 for
120 min at 37uC. A panel of synthetic peptides representing
already known T-cell epitopes was included in the same assay as
reference. Sixty thousand HLA-DQ2 homozygous EBV-trans-
formed B lymphoblastoid cells were irradiated (75 Gy) and
incubated overnight with different concentrations of the TG2-
treated peptides. On day one, 40 000 T cells were added. On day
three, 1 mCi
3H-thymidine was added per well and T-cell
proliferation was measured on day 4 as thymidine incorporation.
The HLA-restriction of the T-cell lines TCL.422.02.2.4 and
TCL.497.C.1.3 was assessed by blocking recognition of TG2-
treated peptide #25 (10 mM) using 5 mg/ml anti-DR (B8.11),
anti-DQ (SPV-L3), or anti-DP (B7/21) specific monoclonal
antibodies during B cell and antigen co-incubation.
Results
Validation of the procedure to identify the best TG2
substrates
Incubation of a PTCEC digest of whole wheat gluten with small
amounts of the primary amine 5-BP and TG2 will result in
transamidation of a limited number of gluten peptides. In order to
detect and identify these TG2 peptide substrates in such a
heterogeneous peptide mixture, transamidated and hence bioti-
nylated peptides were enriched using magnetic streptavidin beads
(Fig. 1). First, we tested the specificity of the enrichment method
for transamidated peptides. Two synthetic peptides known to be
substrates for TG2, DQ2-a-I and DQ2-c-II, were each incubated
with TG2 in the presence of 5-BP. Both samples were spiked into a
PTCEC digest of gluten and streptavidin beads were added.
Analysis by MALDI-TOF mass spectrometry before and after
enrichment demonstrated a high specificity of the enrichment
procedure as only the transamidated DQ2-a-I and DQ2-c-II
peptides were detected after elution from streptavidin beads
(Fig. 2). The transamidated peptides were not observed prior to
enrichment.
We next tested whether the deamidation and transamidation
reactions catalyzed by TG2 prefer the same gluten peptides.
Previously we have shown that epitope peptides DQ2-a-II and
DQ2-c-II undergo rapid deamidation by TG2, whereas epitope
peptides DQ2-c-III and DQ2-c-IV are poorly deamidated [21].
Equal amounts of these four peptides were mixed with a limited
amount of 5-BP and incubated with TG2 for different periods of
time. The transamidated peptides were enriched from the samples
and MALDI-TOF spectra were acquired. The relative signal
intensities of the transamidated DQ2-a-II and DQ2-c-II epitope
peptides increased much faster over time than those of the DQ2-c-
III and DQ2-c-IV epitope peptides suggesting that the former are
better substrates of TG2 (data not shown). This finding is
consistent with previously reported data for deamidation of these
four peptides [21]. Further, we digested a single recombinant a2-
gliadin protein by chymotrypsin and we used this more
heterogeneous gluten peptide mixture to test which peptides were
deamidated and transamidated. For both reactions, the a33mer
peptide (Table 1) and the peptide VRVPVPQLQPQNPSQQQ-
PQEQVPL were identified as substrates. Thus we concluded that
enrichment of gluten peptides by means of crosslinking with 5-BP
can be used to provide information as to which peptides in a
heterogeneous mixture are preferred also for the deamidation
reaction. The method can also determine which glutamine
residues within the preferred substrates are targeted by the
enzyme.
TG2 Selects Gluten Epitopes
PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e14056Identification of enriched gluten peptides by mass
spectrometry
In order to identify optimal TG2 gluten peptide substrates, a
PTCEC digest of whole gluten was incubated with TG2 in the
presence of limiting amounts of 5-BP for 30 minutes. After specific
enrichment of transamidated gluten peptides by magnetic
streptavidin beads, eluted peptides were identified by LC-MS/
MS analysis and subsequent database searching (Fig. 1). Altogeth-
er, 31 different peptide sequences were identified from the
enriched sample of transamidated gluten peptides (Table 2). The
targeted glutamine (Q) residues in these peptides were typically in
the QXP-motif which is in accordance with previous results
regarding TG2 specificity [10,11]. Remarkably, the majority of
the identified peptides contained complete or truncated versions of
known gluten T-cell epitopes (Tables 1 and 2). Among the
identified nine a-gliadin derived peptides, five peptides harbored
at least two of the DQ2-a-I, DQ2-a-II or DQ2-a-III epitopes. The
DQ2-a-II epitope was present in all of the five peptides in one or
two copies (peptides #1–5), while the DQ2-a-I and DQ2-a-III
epitopes were present in peptides #3–5 and peptides #1–3,
respectively. The a-gliadin derived peptide #6 harbored an
incomplete Glia-a20 epitope. The a-gliadin derived 33mer
peptide that is known to be a superior TG2 substrate was not
identified. However, several isoforms (peptides #3 and #5) and
truncated versions (peptides #1, #2, and #4) of this peptide were
observed. The a-gliadin derived peptides #7–9 did not harbor any
known T-cell epitopes. Peptide #7 is similar to the p31–44 ‘‘toxic’’
peptide previously reported except a L to P substitution at the N-
terminus [24].
Ten peptides derived from c-gliadin were identified, and eight
of these peptides contained parts of the DQ2-c-II epitope (peptides
#10–17). Notably, these peptides shared the same peptide core
region but differed in their N- and C-terminal extensions. The
DQ2-c-VIIb/DQ8-c-I epitope was present in one of the identified
c-derived peptides (peptide #18).
Twelve identified peptides derived from glutenin proteins. The
complete DQ2-restricted glutenin-17 epitope, Glt-17, was present
in three of these peptides (peptides #21, #22 and #24) while two
of the peptides (peptides #20 and #23) harbored truncated
versions of the epitope. Interestingly, several of the other identified
TG2 peptide substrates of glutenin proteins have sequences similar
to known epitopes.
Identification of two novel candidate T-cell epitopes
Five of the identified TG2 peptide substrates that did not
contain any known T-cell epitopes had sequences suggesting
potential binding to HLA-DQ2.5 (a negative charge in one of the
anchor positions P4, P6 or P7 [4–6]; no proline residues in
positions P2, P4, P7 or P9 [14]). In an attempt to identify new T-
cell epitopes, we therefore tested these peptides for recognition by
twenty gluten reactive, polyclonal T-cell lines generated from
intestinal biopsies of HLA-DQ2.5 positive celiac disease patients.
The following peptides were tested: peptide #9 (VPVPQL-
QPQNPSQQQPQEQVPL) which also contains peptide #8, peptide
#19 (PHQPQQQVPQPQQPQQPF), peptide #25 (SHQQQPFP-
QQPYPQQPYPS) and peptide #30 (SFPQPQPQQPQQ-
PS; predicted HLA-DQ2.5 binding registers are underlined or in
italics; Q residues targeted by TG2 are in bold). Peptides were
treated with TG2 and tested together with a panel of known gluten
epitopes as reference in a T-cell proliferation assay. While none of
the T-cell lines responded to peptides #9 and #30, the three T-
cell lines TCL.BW.CD-E, TCL.497.C.1.3 and TCL.422.02.2.4
responded to peptide #25 in a TG2-dependent and dose-
dependent fashion (Fig. 3A–C). Interestingly, peptide #25 was
Figure 1. Schematic view of the established method to enrich
and analyze TG2 peptide substrates. A PTCEC digest of wheat
gluten was mixed with a small amount of 5-BP which served as a
substrate for TG2 in a transamidation reaction. The transamidated,
biotinylated peptides were enriched from the digest using magnetic
streptavidin beads, eluted with an excess of biotin and analyzed by LC-
MS/MS. Database searching was performed using a database made up
of all entries of Triticum aestivum present in the Uniprot database. In
addition, MS/MS spectra were manually inspected.
doi:10.1371/journal.pone.0014056.g001
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indicating that there is no cross-reactivity between this peptide and
the DQ2-c-VI epitope which has a very similar sequence. The T-
cell line TCL.BW.CD-E in addition gave a weaker, but specific
response to peptide #19. We thus conclude that peptide #25 and
peptide #19 harbor two novel candidate T-cell epitopes.
Transamidation and deamidation of distinct glutamine
residues within the same peptide
Four a-gliadin and one c-gliadin derived TG2 peptide
substrates were observed as derivatives carrying both a transami-
dated and a deamidated glutamine residue. For peptide #1
(PQPQLPYPQPQLPYPQPQPF), transamidation and deamida-
tion sites could be assigned to Q11 and Q4 (underlined),
respectively. A transamidated and deamidated derivative was also
observed for an elongated version of peptide #1. In this 25mer a-
gliadin peptide (peptide #3, QLQPFPQPQLPYPQPQLPYPQP-
QPF, targeted Q residues underlined), it could however not be
unambiguously determined which of the two targeted glutamine
residues (Q9 and Q16) was transamidated or deamidated. For
peptide #8 (LQPQNPSQQQPQEQVPL), Q14 was found to be
transamidated whereas Q9 was deamidated. These modifications
were observed for the same glutamine residues in peptide #9
which represents an N-terminally extended derivative of peptide
#8. The c-gliadin derived peptide VQGQGIIQPQQPA (peptide
#13) was identified to be transamidated at the Q4 residue and
deamidated at the Q10 residue.
Discussion
In this study we have identified the preferred substrates of TG2
in proteolytic digests of whole wheat gluten. To simplify the
identification we established an enrichment method which is based
on the TG2-mediated transamidation reaction followed by
sequence determination by mass spectrometry. We identified 31
different peptide substrates of TG2. Strikingly, the majority of
these peptides harbor known gluten T-cell epitopes.
To date, more than 15 HLA-DQ2.5 and HLA-DQ8-restricted
gluten derived T-cell epitopes have been identified [12–19]. For
the majority of HLA-DQ2.5-restricted gliadin epitopes, the
kinetics of TG2-mediated deamidation was recently determined
and large variations between the peptide epitopes were observed
[21]. Interestingly, there seems to be a correlation between the
level of deamidation of the different epitopes and how frequently
the epitopes are recognized by T-cells of celiac disease patients.
Peptide substrates of TG2 can be either transamidated or
deamidated. Deamidated reaction products generated in the
absence of primary amines can be directly detected by LC-MS in
mixtures of low complexity, e.g. in a chymotryptic digest of a single
recombinant gliadin protein. However, in our hands this approach
Figure 2. Specific enrichment of transamidated peptides. A PTCEC digest of whole gluten was spiked with the transamidated DQ2-a-I and
DQ2-c-II peptides. MALDI-TOF spectra before (upper panel) and after enrichment (lower panel) are shown. The inset shows the four signals obtained
for each of the two enriched peptides that correspond to the transamidated peptide, its sodium adduct, its potassium adduct and the adduct with
two sodium ions, respectively. All signals observed in the lower mass range (up to m/z 900) were derived from matrix clusters.
doi:10.1371/journal.pone.0014056.g002
TG2 Selects Gluten Epitopes
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e14056was not feasible for the identification of the best substrates of TG2
when analyzing the PTCEC digest of whole gluten because of its
extreme heterogeneity. Although the propensity for either of the
two modifications may differ slightly for some peptide substrates,
the substrate specificity for deamidation and transamidation
overall appears very similar [23]. We confirmed this notion, as
we found the same two peptides being substrates in the
deamidation and transamidation reaction when testing a chymo-
tryptic digest of a recombinant gliadin protein. Moreover, when
testing substrate potency of four peptides for transamidation and
deamidation, we observed the same rank order for the peptides in
both reactions. We therefore decided to harness the transamida-
tion reaction to identify the best peptide substrates in the complex
peptide mixture of a PTCEC digest of whole gluten. By this
approach, we were able to tremendously reduce the sample
complexity by enriching for the TG2-modified peptides and
thereby facilitating identification of individual peptides.
The transamidation reaction in this highly competitive
environment was performed in the presence of limited amounts
of 5-BP and short incubation periods. It is striking that the
majority of the identified transamidated peptides contained intact
known T-cell epitopes or truncated versions thereof. Five of the
nine identified a-gliadin derived peptides carry more than one
copy of either of the epitopes DQ2-a-I, DQ2-a-II, or DQ2-a-III,
and eight of the ten identified c-gliadin peptides harbor a part of
the DQ2-c-II epitope. These epitopes showed also the highest
deamidation rates in our recent study [21], and they constituted
nearly half of the gluten-TG2 substrates we identified.
The identified TG2 substrates that carry T-cell epitopes can be
dichotomized according to whether they harbor complete or
incomplete 9mer core binding regions. Interestingly, this classifi-
cation correlates with the frequency by which the T-cell epitopes
are recognized by T cells of celiac disease patients. T-cell epitopes
that are frequently recognized by T cells of celiac disease patients
(e.g. DQ2-a-I, DQ2-a-II/DQ2-a-III) were represented by their
intact 9mer sequences whereas the T-cell epitopes that are
infrequently recognized (e.g. DQ2-c-II, Glia-a20, Glt-17) were
represented by partial 9mer sequences. This was particularly
striking for the DQ2-c-II epitope which was never represented by
a complete 9mer, but appeared in C-terminally truncated forms in
8 distinct peptides. In keeping with our results, Shan et al. reported
that the DQ2-c-II epitope was not among the most proteolytically
stable fragments of a recombinant c-gliadin protein [20]. These
data underscore that proteolytic degradation is an important force
in the selection of gluten T-cell epitopes in celiac disease.
Among the peptides selected as substrates by TG2 we identified
sequences that are likely to contain novel T-cell epitopes. Five
peptides that did not harbor already known T-cell epitopes were
suspected to be T-cell stimulatory as their sequences indicated
potential HLA-DQ2.5 binding. We tested synthetic peptides
representing these five sequences for recognition by twenty
polyclonal T-cell lines of HLA-DQ2.5-positive celiac disease
patients. Two of them, peptide #19 and peptide #25, elicited
dose-dependent T-cell responses in one or more T-cell lines.
Peptides #8 and #9, which are found in the well-investigated a2-
gliadin protein, have also been reported as substrates for TG2 [25]
and their sequences suggest that they may bind to HLA-DQ2.5. In
keeping with previous findings [12,26], our results indicate
however that these peptides do not harbor T-cell epitopes. The
sequences of the remaining peptides (#7, #28, #29, and #31) do
Table 1. Identified T-cell epitopes in wheat gluten and their observed T-cell response in celiac disease patients.
T-cell epitopes Peptide binding register (P1–P9) T-cell response Identified
DQ2-a-I PFPQPQ LPY 8/14 [34] 12/17 [12] 7/20 [17] !
DQ2-a-II PQPQ LPYPQ 14/14 [34]
a 10/20 [17]
a 11/17 [12]
a !
DQ2-a-III PYPQPQ LPY 14/14 [34]
a 10/20 [17]
a 11/17 [12]
a !
DQ2-c-I PQQSFPQ Q Q 3/14 [34]
DQ2-c-II IQPQ QPAQL 4/14 [34] 5/13 [14] !¤
DQ2-c-III/DQ8-c-I Q QPQ QPYPQ 6/14 [34]
b
DQ2-c-IV SQPQ Q Q FPQ 3/13 [14]
DQ2-c-VI Q QPFPQ QPQ 6/14 [34]
b
DQ2-c-VII PQPQ Q Q FPQ -
DQ2-c-VIIb/DQ8-c-I Q QPQ QPFPQ 3/13 [14] !
Glia-a20 FRPQ QPYPQ 4/20 [17] !¤
Glt-17 PFSQ Q Q QPV
c !
DQ8-a-I Q GSFQPSQQ -
DQ8-glutenin Q GYYPTSPQ -
v17mer QPQQPFPQPEQPFPWQP 5/14 [30]
c26mer FLQPQQPFPQQPQQPYPQQPQQPFPQ -
a33mer LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF 14/14 [34] 13/13 [14]
Glutamine residues expected to be targeted by TG2 are given in bold.
aPeptide PQPQLPYPQPQLPY harboring both epitopes, DQ2-a-II and DQ2-a-III, was tested.
bPeptide LQPQQPFPQQPQQPYPQQPQ harboring both epitopes, DQ2-c-III/DQ8-c-I and DQ2-c-VI, was tested.
cNote that this peptide is not identical to peptide QQPPFSQQQQQPLPQ which was previously known as the ‘‘Glt-17’’ epitope. Peptide QQPPFSQQQQQPLPQ has
previously been tested for T-cell response in CD patients: 3/20 [17].
¤Identified TG2 peptide substrates that harbor incomplete 9mer core binding regions.
doi:10.1371/journal.pone.0014056.t001
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# Peptide identified Modifications Protein (
a) T-cell epitope
Intact 9mer
core
1 PQPQLPYPQPQLPYPQPQPF 5-BP: Q11 a-gliadin (3) DQ2-a-II (26), DQ2-a-III Yes
PQPQLPYPQPQLPYPQPQPF 5-BP: Q4 Yes
PQPQLPYPQPQLPYPQPQPF 5-BP: Q11, DA. Q4 Yes
2 LPYPQPQLPYPQPQPF 5-BP: Q7 a-gliadin (3) DQ2-a-II, DQ2-a-III Yes
3 QLQPFPQPQLPYPQPQLPYPQPQPF 5-BP: Q9/Q16
b a-gliadin (3) DQ2-a-I, DQ2-a-II (26), DQ2-a-III Yes
QLQPFPQPQLPYPQPQLPYPQPQPF 5-BP: Q9/Q16, DA: Q9/
Q16
c
Yes
4 QLQPFPQPQLPYPQPQ 5-BP: Q9 a-gliadin (5) DQ2-a-I, DQ2-a-II Yes
5 QLQPFPQPQLPYPQPQPF 5-BP: Q9 a-gliadin (4) DQ2-a-I, DQ2-a-II Yes
6 RPQQPYPQPQPQ 5-BP: Q3 a-gliadin (9) Glia -a20 No
7 LGQQQPFPPQQPYPQPQPFPS 5-BP: Q3/Q4
b a-gliadin (3)
8 LQPQNPSQQQPQEQVPL 5-BP: Q14 a-gliadin (6)
LQPQNPSQQQPQEQVPL 5-BP: Q14, DA: Q9
9 VPVPQLQPQNPSQQQPQEQVPL 5-BP: Q19 a-gliadin (4)
VPVPQLQPQNPSQQQPQEQVPL 5-BP: Q19, DA: Q14
10 GIIQPQQPA 5-BP: Q6 c-gliadin (20) DQ2-c-II No
11 VQGQGIIQPQ 5-BP: Q4
d c-gliadin (20) DQ2-c-II No
12 VQGQGIIQPQQ 5-BP: Q4 c-gliadin (20) DQ2-c-II No
13 VQGQGIIQPQQPA 5-BP: Q4 c-gliadin (20) DQ2-c-II No
VQGQGIIQPQQPA 5-BP: Q4, DA: Q10 No
14 VQGQGIIQPQQPAQ 5-BP: Q4 c-gliadin (20) DQ2-c-II No
15 LVQGQGIIQPQQPA 5-BP: Q5 c-gliadin (20) DQ2-c-II No
16 LVQGQGIIQPQQPAQ 5-BP: Q5 c-gliadin (20) DQ2-c-II No
17 QLVQGQGIIQPQQPAQ 5-BP: Q6 c-gliadin (20) DQ2-c-II No
18 SQQPQQPFPQPQ or SQQPQQPFPQQP 5-BP: Q2 c-gliadin (9) DQ2-c-VIIb/DQ8-c-I Yes
19 PHQPQQQVPQPQQPQQPF 5-BP: Q12 c-gliadin (7) New candidate epitope Yes
20 SQQQQPVLPQQQPV
e 5-BP: Q2/Q3/Q4
b LMW glutenin (2) Glt-17 No
21 SQQQPPFSQQQQPV 5-BP: Q11 LMW glutenin (6) Glt-17 Yes
22 SQQQPPFSQQQQPVxPQQPS
e 5-BP: Q9/Q10/Q11
b LMW glutenin (2/3) Glt-17 Yes
23 SQQQQPVxPQQPS
e 5-BP: Q2/Q3/Q4
b LMW glutenin (2/1) Glt-17 No
24 PQQPPFSQQQQPVLPPQQSPFPQ
e 5-BP: Q10 LMW glutenin (5) Glt-17 Yes
25 SHQQQPFPQQPYPQQPYPS
f 5-BP: Q14 LMW glutenin (1) New candidate epitope Yes
SHQQQPFPQQPYPQQPYPS
f 5-BP: Q9 Yes
26 PQQPPFSQQQQPx 5-BP: Q9/Q10
b LMW glutenin (3) Cross-reactive to Glt-17 Yes
27 SQQQQPPFSQQQPPFSQQQQQPL 5-BP: Q20 LMW glutenin (1) Cross-reactive to Glt-17 Yes
28 QQQPPFSQQQPx 5-BP: Q9 LMW glutenin (11)
29 SQQQLPPFSQQQSPF 5-BP: Q2 LMW glutenin (1)
30 SFPQPQPQQPQQPS 5-BP: Q8 LMW glutenin (1), v-
gliadin (1)
31 SQQQQLFPQQPS 5-BP: Q2/Q3/Q4
b LMW glutenin (1)
Glutamine residues targeted by TG2 are given in bold.
DA, deamidation
The 9mer core region of T-cell epitopes are underlined.
‘‘x’’ indicates I or L.
anumber of protein entries in database.
bnot possible to determine which Q residue is transamidated (shown in bold and italic).
cnot possible to determine which Q residue is deamidated and which is transamidated.
dnot possible to determine whether Q2 or Q4 is targeted; however, this sequence has previously been shown to be targeted at Q4 [17]. The same Q residue is expected
to be targeted in peptides #12–17.
eidentified in a sample incubated with TG2 for one minute.
ftwo possible 9mer binding registers to HLA-DQ2.5.
doi:10.1371/journal.pone.0014056.t002
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and they are thus unlikely to be efficient stimulators of T cells from
celiac disease patients.
The immunostimulatory a-gliadin derived 33mer fragment,
which is a very good TG2 substrate and which is resistant to
proteolysis [27], was not among the identified TG2 gluten
substrates. Recently, the occurrence of T-cell epitopes in a-gliadin
proteins of different cultivars was reported [28]. This study found,
as was indicated in an earlier study [29], that the complete a33mer
fragment only exists in a-gliadin proteins encoded in the D-
genome of Triticum aestivum. Thus, the a33mer peptide was likely
present in a low amount in the PTCEC gluten digest we used
which could explain its absence among the identified TG2
substrates. We observed, however, several variants of the a33mer
peptide (peptides #3 and #5) and as well as truncated versions of
these peptides (peptides #1, #2, and #4). Notably, it has been
demonstrated that such shorter versions can be as potent as the
a33mer peptide in stimulating intestinal T-cell responses [30].
Among the identified TG2 peptide substrates a few peptides
were observed as transamidated and deamidated at the same time.
These findings may have implications for the generation of TG2-
specific autoantibodies in celiac disease whose appearance is
strictly dependent on the dietary intake of gluten [31]. In a
previously proposed hapten-carrier model, uptake of covalent
complexes between TG2 and gluten peptides by TG2-specific B
cells was suggested to result in activation of gluten-specific T cells
which subsequently provide help for the B cells to secrete
antibodies [32]. In accordance with this hypothesis, cross-linking
of gluten peptides to TG2 via generation of isopeptide bonds
between glutamine residues in the peptide and lysine residues of
TG2 has been described [33]. If those TG2-bound gluten peptides
carry an additional deamidated glutamine residue in a T-cell
epitope distant from the transamidation site, e.g. as observed for
peptides #1 and #3, presentation of this epitope would only
require cleavage of the peptide backbone by proteases present in
the endocytic compartments while leaving the isopeptide bond
intact.
In a heterogeneous gluten digest, TG2 is not targeting all the
different gluten peptides, but shows a clear preference for those
which are found as T-cell epitopes in celiac disease patients. This
finding argues for TG2 exerting a strong pressure in the selection
of T-cell epitopes in celiac disease. Our data also demonstrate the
important role of proteolysis in the selection of T-cell epitopes as
the T-cell epitopes that are frequently recognized by T cells of
celiac disease patients more often remain intact than the epitopes
that are infrequently recognized. Together, the selective forces
exerted by TG2 and gastrointestinal proteolysis are key factors to
determine the repertoire of gluten epitopes in celiac disease.
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